Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 2
2002 3
2003 2
2005 1
2006 5
2007 2
2008 3
2009 5
2010 5
2011 5
2012 10
2013 7
2014 3
2015 12
2016 11
2017 9
2018 9
2019 9
2020 2
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17083009

105 results

Results by year

Filters applied: . Clear all
Page 1
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, Diggle L, John TM, Yu LM, Omar O, Borkowski A, Pollard AJ. de Whalley PC, et al. Pediatr Infect Dis J. 2011 Nov;30(11):e203-8. doi: 10.1097/INF.0b013e318224fb14. Pediatr Infect Dis J. 2011. PMID: 21673612 Clinical Trial.
Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM. van Ravenhorst MB, et al. Vaccine. 2017 Aug 24;35(36):4745-4752. doi: 10.1016/j.vaccine.2017.06.053. Epub 2017 Jun 28. Vaccine. 2017. PMID: 28668575 Clinical Trial.
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
Nolan T, Santolaya ME, de Looze F, Marshall H, Richmond P, Henein S, Rheault P, Heaton K, Perrett KP, Garfield H, Gupta A, Ferguson M, D'Agostino D, Toneatto D, O'Ryan M. Nolan T, et al. Vaccine. 2019 Feb 21;37(9):1209-1218. doi: 10.1016/j.vaccine.2018.12.059. Epub 2019 Jan 26. Vaccine. 2019. PMID: 30691980 Free article. Clinical Trial.
Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N. Dbaibo G, et al. Drugs Aging. 2013 May;30(5):309-19. doi: 10.1007/s40266-013-0065-0. Drugs Aging. 2013. PMID: 23494214 Free PMC article. Clinical Trial.
105 results